title: Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy.
authors.forename: Claudia
authors.initials: C
authors.lastname: Cavelti-Weder
authors.forename: Bettina
authors.initials: B
authors.lastname: Muggli
authors.forename: Cornelia
authors.initials: C
authors.lastname: Keller
authors.forename: Andrea
authors.initials: A
authors.lastname: Babians-Brunner
authors.forename: Anna
authors.initials: A
authors.lastname: Biason-Lauber
authors.forename: Marc Y
authors.initials: MY
authors.lastname: Donath
authors.forename: Peter
authors.initials: P
authors.lastname: Schmid-Grendelmeier
mesh_terms: D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood*; D007328:Insulin / Q000009:adverse effects* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D001786:Blood Glucose; D007328:Insulin; D000069444:Omalizumab; D007073:Immunoglobulin E